PubMed

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.

Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL; fracture intervention trial.

Diabetes Care. 2004 Jul;27(7):1547-53.PMID: 15220226 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78. PMID: 8833208 [PubMed - indexed for MEDLINE]Related articles

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.PMID: 11889149 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.

JAMA. 1998 Dec 23-30;280(24):2077-82.PMID: 9875874 [PubMed - indexed for MEDLINE]Related articlesFree article

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ.

J Clin Endocrinol Metab. 1997 Jan;82(1):265-74.PMID: 8989272 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.PMID: 15231012 [PubMed - indexed for MEDLINE]Related articles

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B.

Osteoporos Int. 1999;9(5):461-8.PMID: 10550467 [PubMed - indexed for MEDLINE]Related articles

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A.

Arthritis Rheum. 2001 Jan;44(1):202-11.PMID: 11212161 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.

Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC.

Curr Med Res Opin. 2003;19(5):383-94.PMID: 13678475 [PubMed - indexed for MEDLINE]Related articles

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.PMID: 11238495 [PubMed - indexed for MEDLINE]Related articlesFree article

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

J Bone Miner Res. 1998 Sep;13(9):1431-8.PMID: 9738515 [PubMed - indexed for MEDLINE]Related articles

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; for the Fracture Intervention Research Group.

J Bone Miner Res. 2006 Feb;21(2):292-9. Epub 2005 Oct 31.PMID: 16418785 [PubMed - indexed for MEDLINE]Related articles

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.PMID: 17190893 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.PMID: 15068497 [PubMed - indexed for MEDLINE]Related articles

Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.

Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.

J Am Geriatr Soc. 2007 May;55(5):752-7.PMID: 17493196 [PubMed - indexed for MEDLINE]Related articles

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.PMID: 16884968 [PubMed - indexed for MEDLINE]Related articles

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.

J Clin Endocrinol Metab. 2004 Jul;89(7):3319-25.PMID: 15240609 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL.

Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19.PMID: 17182297 [PubMed - indexed for MEDLINE]Related articles

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.PMID: 9531231 [PubMed - indexed for MEDLINE]Related articles